Clinically, tumor markers, including carcinoembryonic antigen, carbohydrate antigen 125 (CA125), and carbohydrate 199 (CA199), as well as the AJCC staging system, are widely used to evaluate tumor progression and prognosis in the peri-operation of patients with CRC. This evidence concerns the gene CEACAM5 and neoplasm.